AXE has the electrochemical gFET sensor that detects potassium and will now use the optical sensor that Hylidix uses to detect hemolysis, the quality of blood cells, to enhance the detection potassium in blood to a very acceptably safe level of accuracy. That's electrochemical plus optical detection. No coincidence that again graphene lends itself to useful modifications to improve optical or photochemical properties. Hylidx could get AXE expertise in nanoengineering to enhance their own sensors as well.
No doubt the aim is to make the FDA approvals as straight forward as possible. The language AXE has used in past couple of announcements indicates a prototype packaged for testing by end of 2025. It might even be sooner. This is now in the sausage machine, we just wait for the gourmet packaging at the other end hopefully.
AXE Price at posting:
32.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)